Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetically Informed Smoking Cessation Trial
NCT02351167Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2015
- Primary completion
- Dec 2018
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in nicotine dependence comparing Combination NRT, Varenicline and Placebo (3 arms). Primary endpoint: 7-day Point Prevalence Quit Rate at 12 weeks. Started May 2015; status: completed.
02
Drugs
nicotine patchvarenicline + nicotine patch
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT02351167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351167.